Select Page


POLYGON Therapeutics announces a collaboration with GTP Bioways for the development of its flagship molecule, PLG-101


Paris, Toulouse – February 28th, 2023. POLYGON, a Paris-based preclinical-stage biotech company, is announcing a collaboration with GTP Bioways for the cell line development of its innovative biotherapeutics aiming to improve the outcome of cardiovascular diseases and acute immune disorders. The goal of the partnership is to develop robust and scalable cell lines for the production of biopharmaceuticals.

Polygon Therapeutics and GTP Bioways collaborates for cell line development

With a highly committed and experienced team of scientists and researchers, POLYGON is dedicated to delivering innovative and effective therapies, to the 500+ million people affected by cardiovascular conditions worldwide, with a focus on acute events. Its goal is to provide new hope to patients and families affected by these diseases and to have a positive impact on the global healthcare landscape.

The company’s lead product, PLG-101, is a cutting-edge therapy to treat acute immune-related cardiovascular disease. This specific monoclonal antibody targets CD8+ T cells, a type of immune cell that plays a key role in the development of cardiac damages after myocardial infarction. By targeting CD8+ T cells, PLG-101 has the potential to prevent the damaging effects of the specific immune reaction.

“We are delighted to partner with GTP Bioways to develop a cell line for the industrial manufacturing of our molecule,” says Mohamed Abou Ali, CEO of POLYGON Therapeutics. “Our collaboration will help us develop a highly efficient and scalable cell line, which will support the production of our product that can make a difference in people’s lives.”

GTP Bioways will develop a unique cell line able to produce the desired biomolecule at a large scale, allowing the project to move from preclinical phase towards the manufacturing of the biotherapeutic for clinical stage.

“We are thrilled to support this project. Our experienced team will develop the cell line during the first semester of 2023, allowing Polygon to meet its deadlines. We will support POLYGON with all the required documentation for a smooth clinical development”, says Eric Devic, general manager of GTP Bioways.


About Polygon Therapeutics

POLYGON Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from cardiovascular diseases and acute immune disorders. Its main drug is a first-in-class monoclonal antibody, PLG-101.

Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: in recent times, 18 million people have died annually from CVDs, representing 31% of all global deaths. Among these deaths, 85% are due to heart attacks and strokes. Despite a better management of risk factors (e.g. hypercholesterolemia and hypertension) and significant progress in CVD care, new therapeutic approaches remain untapped.

POLYGON’s first therapeutic solution, PLG-101, aims to target a specific immune response happening during myocardial infarction to enhance post-ischemic cardiac remodeling. It has already shown successful results on mice and pig models. Potential in other cardiovascular indications has been highlighted.

About GTP Bioways

GTP Bioways is a CDMO (Contract Development and Manufacturing Organisation) offering integrated manufacturing services to support biopharma companies from preclinical to commercial production of their innovative therapies. Our expertise and capabilities cover the manufacturing of biologics (mammalian and microbial processes), antibody-drug-conjugates, and sterile nanoformulated drug products (vials/PFS). Drawing on our expertise in solving tough client problems, we strive to offer a tailored approach, finely tuned to overcome each specific challenge.

With development and production sites based in France, GTP Bioways supports biopharmaceutical companies aiming to develop innovative molecules, from R&D through to clinical trials. With our unique offer, we expect to generate a turnover of €25M ($23.7M) in 2023. We employ 130 staff.